Gilead Sciences News

FOSTER CITY, Calif. -- -- Gilead Sciences, Inc. announced today that the company will be webcasting its corporate presentation at two upcoming investor conferences: the Jefferies Global Healthcare Conference in New York and the Goldman Sachs Healthcare Conference in Rancho Palos Verdes, California.

May isn't in the books yet, but three health-care stocks have shot to the stratosphere.

FOSTER CITY, Calif. -- -- Gilead Sciences, Inc. announced today that the Marketing Authorisation Application for cobicistat, submitted on April 26, 2012, has been validated by the European Medicines Agency .

Keep track of the stocks that matter to you. Help yourself with the Fool's FREE and easy new watchlist service today.

Gilead Sciences Inc is an innovative healthcare company with a strong record of historical earnings growth and expectations for above-average growth into the future.

Truvada, a once-daily antiretroviral pill, is effective for preventing sexual transmission of HIV and should be approved as post-exposure prophylaxis, or PrEP, a Food and Drug Administration advisory committee voted last week.

Pharmasset, Inc. is a health care pharmaceutical company. The company is engaged in discovering, producing and commercializing medicines to treat viral infections.

New York-based Hedge Fund Baker Bros. Advisors LLC, as of the most recent SEC 13-F Q1 filing , had $3.7 billion in equity assets, almost all invested in the biotech sector, and an increase from the $3.0 billion in Q4 and $2.3 billion in Q3 of 2011.

Netflix, Inc. : Needham believes that increases in Netflix's domestic streaming margins will be largely offset by a decline in higher margin DVD subscription revenues.

NEW YORK, May 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: This report analyzes the worldwide markets for Nanobiotechnology in US$ Million by the following Technology Segments: Nanomaterials , and Nanodevices/Tools. The report provides separate comprehensive analytics for the ... (more)

The New York Times and the Financial Times examine concerns expressed by AIDS activists and members of an FDA panel that last week recommended Gilead Sciences' antiretroviral drug Truvada be approved for pre-exposure prophylaxis to prevent HIV among healthy people at risk of contracting the virus .

Healthcare costs have been on the rise. Annual medical costs increased almost 35% from 2006 to 2010, with healthcare spending rising 8% a year .

The single, easiest way to keep track of all the stocks that matter... Your own personalized stock watchlist! It's a 100% FREE Motley Fool service... ) Quad HIV drug off the market -- an advisory panel recommended approving the drug by a 13-1 margin -- but they might result in extra monitoring for kidney complications once the Quad is on the ... (more)

In trading on Monday, the Biotech ETF is outperforming other ETFs, up about 0.5% on the day.

Contact us Search archives Page Reprints Getting Into Print Weather Our History Privacy Statement RSS Feeds Advertising Webcams >> More blue AP Video News Politics Gazette Charities Business Police Blotter Watchdog News Columnists Putnam County Public records Special Reports Weird News Corrections Advisories >> More blue WVU Marshall Prep Sports ... (more)

Gilead Sciences Inc. 's experimental HIV pill Quad, the new medicine from the world's largest maker of AIDS drugs, gained a U.S. advisory panel's backing to treat patients infected with the virus.

Biz Break: Cisco drags tech stocks down, but two Silicon Valley IPOs find success; also, Microsoft uses Facebook to battle Google Biz Break: Microsoft looks at Nook for tablet anchor, Apple falls below $600 again, and a big day for cleantech This photo provided by Gilead Sciences shows Truvada.

Shares of Gilead continue to rise subsequent to Thursday's FDA advisory panel approval of the firm's HIV drug Truvada for use as a preventative measure in high-risk individuals.

Gilead Sciences Inc.'s HIV drug Truvada won the backing of a U.S. advisory panel as the first medicine to keep healthy people from getting the virus through sexual activity.

FOSTER CITY, Calif. -- -- Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration has voted to support approval of once-daily oral Truvada to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP.